Scandion Oncology Management
Management criteria checks 2/4
Scandion Oncology's CEO is Francois Martelet, appointed in Jan 2023, has a tenure of 2.17 years. directly owns 0.005% of the company’s shares, worth SEK206.81. The average tenure of the management team and the board of directors is 2.7 years and 3.5 years respectively.
Key information
Francois Martelet
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 2.2yrs |
CEO ownership | 0.005% |
Management average tenure | 2.7yrs |
Board average tenure | 3.5yrs |
Recent management updates
Recent updates
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully
Aug 02Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth
Feb 01Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation
May 26We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely
Jan 06CEO
Francois Martelet (64 yo)
2.2yrs
Tenure
Dr. Francois Regis Martelet, M.D., is a Non-executive Director of Novigenix SA since June 2019. He had been the Chief Executive Officer of Vivesto AB (formerly known as Oasmia Pharmaceutical AB (publ)) sin...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Scientific Officer | 2.2yrs | no data | 0.58% SEK 25.0k | |
Chief Executive Officer | 2.2yrs | no data | 0.0048% SEK 206.8 | |
Chief Financial Officer | 3.6yrs | no data | 0.0057% SEK 246.7 | |
General Counsel | no data | no data | no data | |
Head of External Communication | 3.2yrs | no data | no data |
2.7yrs
Average Tenure
Experienced Management: SCOL's management team is considered experienced (2.7 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | 3.9yrs | no data | no data | |
Independent Deputy Chairman of the Board | 2.9yrs | no data | no data | |
Member of Clinical Advisory Board | 3.5yrs | no data | no data | |
Member of Clinical Advisory Board | 3.5yrs | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 2.9yrs | no data | no data | |
Member of Clinical Advisory Board | 3.5yrs | no data | no data | |
Independent Chairman of the Board | 3.8yrs | no data | 0.0027% SEK 115.8 | |
Member of Clinical Advisory Board | less than a year | no data | no data | |
Independent Director | 1.2yrs | no data | no data |
3.5yrs
Average Tenure
63yo
Average Age
Experienced Board: SCOL's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/14 19:34 |
End of Day Share Price | 2025/03/14 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scandion Oncology A/S is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Soo Romanoff | Edison Investment Research |
Christian Binder | Redeye |